10 result(s)
IN VIVO
Ex VIVO
Updated Phase 1 Clinical Trial Outcomes of CRISPR Gene Editing With Nexiguran Ziclumeran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
2025 American Heart Association Scientific Sessions
Two-Year Durability/Safety of One-Time Lonvoguran Ziclumeran (Lonvo-z, NTLA-2002) 50 mg in Patients With Hereditary Angioedema
2025 American College of Allergy Asthma and Immunology Annual Scientific Meeting
Safety/Tolerability of a One-Time Infusion of Lonvoguran Ziclumeran (lonvo-z; NTLA-2002) for Hereditary Angioedema
2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Barriers to Achieving Normalization Among People Living with HAE On Existing Treatments
2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
The New England Journal of Medicine
CRISPR Gene Editing With Nexiguran Ziclumeran in Hereditary ATTR With Polyneuropathy: Phase 1 24-Month Report
5th International ATTR Amyloidosis Meeting for Patients and Doctors
Long-Term Durability of CRISPR-Based Gene Editing of KLKB1 from Phase 1 of a Phase 1/2 trial of Patients with Hereditary Angioedema
2025 European Academy of Allergy and Clinical Immunology Annual Meeting
CRISPR Gene Editing With Nexiguran Ziclumeran in Hereditary ATTR With Polyneuropathy: Phase 1 Interim Report
2025 Peripheral Nerve Society Annual Meeting
CRISPR Gene Editing With Nexiguran Ziclumeran in ATTR Cardiomyopathy: Treatment Effect in Hereditary vs. Wild-Type Disease
Heart Failure Congress 2025
CRISPR-Based NTLA-2002 Improves Quality of Life in Patients With Hereditary Angioedema
American Academy of Allergy, Asthma & Immunology and World Allergy Organization Joint Congress
